PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in March
February 28, 2023 16:05 ET
|
PMV Pharmaceuticals, Inc.
PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 08, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
Enrollment continued in the Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation ...
PMV Pharmaceuticals Appoints Industry Veteran Dr. Carol Gallagher to Board of Directors
November 04, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
PMV Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 09, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
Initial PC14586 Phase 1 data presented at the American Society of Clinical Oncology Annual Meeting (ASCO) demonstrated responses in patients across multiple solid tumor types with a p53 Y220C...
PMV Pharmaceuticals Announces a Clinical Trial Collaboration with Merck to Evaluate PC14586 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
July 18, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
June 08, 2022 08:00 ET
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule,...
PMV Pharmaceuticals Initial PC14586 Phase 1 Data Presented at ASCO Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a p53 Y220C Mutation
June 07, 2022 12:00 ET
|
PMV Pharmaceuticals, Inc.
Overall response rate (ORR) of 32% (8/25) achieved in higher dose cohorts per RECIST v1.1 Partial responses observed across six distinct tumor typesData featured as an oral presentation at ASCO;...
PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2022 17:05 ET
|
PMV Pharmaceuticals, Inc.
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and...
PMV Pharmaceuticals Reports First Quarter 2022 Financial Results and Corporate Highlights
May 10, 2022 07:30 ET
|
PMV Pharmaceuticals, Inc.
Oral presentation at 2022 ASCO annual meeting to highlight initial data from ongoing Phase 1/2 PYNNACLE study of PC14586 in patients with advanced solid tumors CRANBURY, N.J., May 10, 2022...